IN2012DN01981A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01981A
IN2012DN01981A IN1981DEN2012A IN2012DN01981A IN 2012DN01981 A IN2012DN01981 A IN 2012DN01981A IN 1981DEN2012 A IN1981DEN2012 A IN 1981DEN2012A IN 2012DN01981 A IN2012DN01981 A IN 2012DN01981A
Authority
IN
India
Prior art keywords
rgd
disease
diseases
proteins
granuloma
Prior art date
Application number
Other languages
English (en)
Inventor
Shankar Kumar
J Yun Tso
Naoya Tsurushita
Original Assignee
Gene Techno Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Techno Science Co Ltd filed Critical Gene Techno Science Co Ltd
Publication of IN2012DN01981A publication Critical patent/IN2012DN01981A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN1981DEN2012 2009-09-24 2010-09-22 IN2012DN01981A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27243809P 2009-09-24 2009-09-24
PCT/JP2010/067017 WO2011037271A1 (en) 2009-09-24 2010-09-22 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN01981A true IN2012DN01981A (ru) 2015-07-24

Family

ID=43796008

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1981DEN2012 IN2012DN01981A (ru) 2009-09-24 2010-09-22

Country Status (9)

Country Link
US (1) US8617829B2 (ru)
EP (1) EP2480665A4 (ru)
JP (1) JP5781504B2 (ru)
KR (1) KR101809761B1 (ru)
CN (1) CN102712921B (ru)
AU (1) AU2010299017B2 (ru)
CA (1) CA2772230C (ru)
IN (1) IN2012DN01981A (ru)
WO (1) WO2011037271A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160045552A1 (en) * 2013-04-08 2016-02-18 Asana Medical, Inc. Method and composition for treating inflammatory bowel disease without colectomy
US10829560B2 (en) 2015-04-20 2020-11-10 Consejo Superior De Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
BR112019010064A2 (pt) * 2016-11-18 2019-10-01 Astellas Pharma Inc novo fragmento fab do anticorpo muc1 anti-humano
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
IL145891A0 (en) 1999-04-15 2002-07-25 Childrens Medical Center Methods and compositions for modulating an immune response
JP2003528322A (ja) 2000-03-23 2003-09-24 グラクソ グループ リミテッド オステオポンチンのインヒビターのスクリーニング方法
JP2007106767A (ja) * 2001-04-05 2007-04-26 Meneki Seibutsu Kenkyusho:Kk 抗オステオポンチン抗体およびその用途
BR0208809A (pt) 2001-04-05 2004-03-09 Immuno Biolog Labiratories Co Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo
RU2305111C2 (ru) 2001-09-25 2007-08-27 Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют Рекомбинантное антитело против остеопонтина и его применение
JPWO2004103403A1 (ja) 2003-05-23 2006-07-20 株式会社 免疫生物研究所 免疫担当細胞活性化阻害剤およびその用途
CA2667263C (en) * 2006-10-26 2016-11-08 Gene Techno Science Co., Ltd. Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same
US8614296B2 (en) * 2008-04-24 2013-12-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof

Also Published As

Publication number Publication date
KR20120078725A (ko) 2012-07-10
JP5781504B2 (ja) 2015-09-24
EP2480665A4 (en) 2013-04-03
CN102712921B (zh) 2017-03-01
CA2772230C (en) 2019-01-08
JP2013505702A (ja) 2013-02-21
CN102712921A (zh) 2012-10-03
AU2010299017B2 (en) 2014-02-06
AU2010299017A1 (en) 2012-03-15
EP2480665A1 (en) 2012-08-01
KR101809761B1 (ko) 2017-12-15
WO2011037271A1 (en) 2011-03-31
US20120219503A1 (en) 2012-08-30
US8617829B2 (en) 2013-12-31
CA2772230A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
EP2388323A3 (en) Humanized anti-9 integrin antibodies and the uses thereof
NZ594315A (en) Antibody molecules having specificity for human ox40
NZ606587A (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
JO3375B1 (ar) أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
IN266863B (ru)
MX2019007708A (es) Nuevos agentes anti-inflamatorios.
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
UA115540C2 (uk) Антитіло до il-36r
TW200740844A (en) Novel MAdCAM antibodies
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
MX2011011729A (es) Anticuerpo anti il-17f y metodos de uso de los mismos.
EP2037961A4 (en) METHODS OF TREATING AUTOIMMUNE DISORDERS USING MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY
MX2013013329A (es) Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos.
MY151045A (en) Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
JO3327B1 (ar) تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن
NZ604643A (en) S100a4 antibodies and therapeutic uses thereof
IN2012DN01981A (ru)
NZ601271A (en) Cd127 binding proteins
FI3172232T3 (fi) TREM-1-vasta-aineiden kohdennettu mutageneesi viskositeetin alentamista varten
FR2959994B1 (fr) Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
EA201291345A1 (ru) Цитруллинированные гистоновые пептиды и их применение
HRP20141110T1 (hr) Poboljšano humanizirano anti-humani alfa9-integrin-protutijelo
NZ602906A (en) Novel interferon-alpha-producing bone marrow dendritic cells
WO2011020933A8 (es) Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail